A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Inclusion Criteria

• Participant must be ≥ 18 years of age.
• Histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with any of the following tumor types:.
• Part 1A: clear-cell renal cell carcinoma (ccRCC), clear-cell ovarian cancer (ccOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC).
• Parts 2A, 1D, 2D: ccRCC. i) Part 1B: solid tumors with KRAS G12C mutation. ii) Part 2B: NSCLC with KRAS G12C mutation. iii) Parts 1C, 2C: colorectal cancer (CRC) with KRAS G12C mutation.
• Participants must have an Eastern Cooperative Oncology Groups (ECOG) Performance Status of 0 or 1.
• Participants must have measurable disease per RECIST v1.1.

Exclusion Criteria

• Untreated central nervous system (CNS) metastases.
• Leptomeningeal metastasis (carcinomatous meningitis).
• Impaired cardiac function or clinically significant cardiac disease.
• For Parts 1B, 1C, 2B, 2C only (combination with adagrasib):. i) History of pneumonitis or interstitial lung disease (ILD). ii) History of prior severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
• Other protocol-defined inclusion/exclusion criteria apply.